Literature DB >> 34917209

Challenging endovascular treatment for the patient with chronic limb threatening ischemia due to antiphospholipid syndrome.

Wataru Takahashi1, Takehiro Morita1, Kiu Tanaka1, Shougo Ide1, Kouki Hujimori1.   

Abstract

Vascular surgery for chronic limb threatening ischemia (CLTI) in patients with antiphospholipid syndrome (APS) has a poor outcome with a high rate of postoperative thrombotic complications. However, there is little data regarding outcomes of endovascular treatment (EVT). This manuscript reports an interesting case of APS with CLTI in which timely EVT and continuous anticoagulant therapy not only prevented amputation but also thrombotic events over a long period of time. A 41-year-old man with CLTI in the left lower limb was seen and examined. Contrast-enhanced computed tomography revealed thrombotic occlusion in both iliac arteries and the left popliteal artery. Activated partial thromboplastin time was prolonged, and anti-β2 glycoprotein I antibodies and lupus anticoagulants were present. After starting antithrombotic therapy with warfarin, EVT was performed using self-expandable stents in both iliac arterial lesions, and a marked reduction in limb ischemia was observed. Furthermore, the patient was free from thrombotic events for six years until a change in the anticoagulant led to stent thrombosis. This case suggests that EVT using stents along with continuous antithrombotic therapy with warfarin in patients with APS and CLTI could be very effective for immediate relief of ischemia and long-term reduction in thrombotic events. <Learning objective: APS is a rare but important cause of CLTI, and outcomes in patients with APS who receive vascular surgery for CLTI are poor because of a high rate of postoperative thrombotic complications. EVT using a stent can be a useful option if it is coupled with sustained antithrombotic therapy using a vitamin K antagonist, namely warfarin. In addition, administering direct oral anticoagulants as anticoagulant therapy following EVT in APS patients should be very carefully considered.>.
© 2021 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antiphospholipid syndrome; Critical limb ischemia; Endovascular treatment

Year:  2021        PMID: 34917209      PMCID: PMC8642635          DOI: 10.1016/j.jccase.2021.04.021

Source DB:  PubMed          Journal:  J Cardiol Cases        ISSN: 1878-5409


  9 in total

1.  Antiphospholipid syndrome and recurrent thrombotic valve disease.

Authors:  Dawn C Scantlebury; Vuyisile T Nkomo; Maurice Enriquez-Sarano
Journal:  J Am Coll Cardiol       Date:  2013-06-11       Impact factor: 24.094

2.  Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies.

Authors:  G Ruiz-Irastorza; M J Cuadrado; I Ruiz-Arruza; R Brey; M Crowther; R Derksen; D Erkan; S Krilis; S Machin; V Pengo; S Pierangeli; M Tektonidou; M Khamashta
Journal:  Lupus       Date:  2011-02       Impact factor: 2.911

3.  Contemporary outcomes after endovascular treatment for aorto-iliac artery disease.

Authors:  Yoshimitsu Soga; Osamu Iida; Daizo Kawasaki; Yasutaka Yamauchi; Kenji Suzuki; Keisuke Hirano; Ryoji Koshida; Daisuke Kamoi; Junichi Tazaki; Michiaki Higashitani; Yoshiaki Shintani; Terutoshi Yamaoka; Shinya Okazaki; Nobuhiro Suematsu; Taketsugu Tsuchiya; Yusuke Miyashita; Norihiko Shinozaki; Hiroki Takahashi
Journal:  Circ J       Date:  2012-08-02       Impact factor: 2.993

Review 4.  Successful Endovascular Treatment for Aortic Thrombosis Due to Primary Antiphospholipid Syndrome: A Case Report and Literature Review.

Authors:  Yoshito Kadoya; Kan Zen; Yohei Oda; Satoaki Matoba
Journal:  Vasc Endovascular Surg       Date:  2018-08-09       Impact factor: 1.089

5.  Surgical Interventions for Organ and Limb Ischemia Associated With Primary and Secondary Antiphospholipid Antibody Syndrome With Arterial Involvement.

Authors:  Carlos A Hinojosa; Javier E Anaya-Ayala; Karla Bermudez-Serrato; Ramón García-Alva; Hugo Laparra-Escareno; Adriana Torres-Machorro; Rene Lizola
Journal:  Vasc Endovascular Surg       Date:  2017-09-18       Impact factor: 1.089

6.  Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients.

Authors:  Ricard Cervera; Jean-Charles Piette; Josep Font; Munther A Khamashta; Yehuda Shoenfeld; María Teresa Camps; Soren Jacobsen; Gabriella Lakos; Angela Tincani; Irene Kontopoulou-Griva; Mauro Galeazzi; Pier Luigi Meroni; Ronald H W M Derksen; Philip G de Groot; Erika Gromnica-Ihle; Marta Baleva; Marta Mosca; Stefano Bombardieri; Frédéric Houssiau; Jean-Christophe Gris; Isabelle Quéré; Eric Hachulla; Carlos Vasconcelos; Beate Roch; Antonio Fernández-Nebro; Marie-Claire Boffa; Graham R V Hughes; Miguel Ingelmo
Journal:  Arthritis Rheum       Date:  2002-04

7.  Lower limb ischaemia in primary antiphospholipid syndrome.

Authors:  S Nitecki; B Brenner; A Hoffman; N Lanir; A Schramek; S Torem
Journal:  Eur J Vasc Surg       Date:  1993-07

8.  Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases.

Authors:  Flavio Signorelli; Felipe Nogueira; Vinicius Domingues; Henrique Ataide Mariz; Roger A Levy
Journal:  Clin Rheumatol       Date:  2015-07-30       Impact factor: 2.980

9.  Long-term outcome of infrainguinal bypass grafting in patients with serologically proven hypercoagulability.

Authors:  Michael A Curi; Christopher L Skelly; Zachary K Baldwin; David H Woo; Joseph M Baron; Tina R Desai; Daniel Katz; James F McKinsey; Hisham S Bassiouny; Bruce L Gewertz; Lewis B Schwartz
Journal:  J Vasc Surg       Date:  2003-02       Impact factor: 4.268

  9 in total
  1 in total

1.  There is no consensus among guidelines/consensus reports concerning the optimal management of patients with antiphospholipid syndrome and an arterial event.

Authors:  Mustafa Vakur Bor
Journal:  J Cardiol Cases       Date:  2022-04-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.